Patents by Inventor Lars Gedda

Lars Gedda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150118694
    Abstract: A method for assessing if an individual or an animal has a selected condition includes: obtaining a biological sample from the individual or animal; detecting in a time-resolved manner the presence of a disease related target through use of a probe (111); calculating a multidimensional fingerprint (141) which represents the recorded binding curves (131); extracting a predefined region (151) or feature of the distribution; and using the region or feature to determine (170) if the individual or animal has the selected condition. The method is particularly advantageous for tissue slices combined with antibody probes, the antibody recognizing receptors known to be over-expressed in cancer. In even more particular, a method for the assessment of HER2 expression level in breast cancer is described.
    Type: Application
    Filed: May 30, 2013
    Publication date: April 30, 2015
    Applicant: RIDGEVIEW DIAGNOSTICS AB
    Inventors: Karl Andersson, Magnus Malmqvist, Lena Lebel, Hanna Bjorkelund, Lars Gedda
  • Patent number: 8609135
    Abstract: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumors. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: December 17, 2013
    Assignee: Nuclisome AB
    Inventors: Katarina Edwards, Stefan Sjöberg, Jörgen Carlsson, Lars Gedda
  • Publication number: 20100092388
    Abstract: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumours. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.
    Type: Application
    Filed: October 13, 2009
    Publication date: April 15, 2010
    Inventors: Katarina Edwards, Stefan Sjöberg, Jörgen Carlsson, Lars Gedda
  • Publication number: 20070258890
    Abstract: The present invention relates to new anthracycline derivatives and their use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumours. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.
    Type: Application
    Filed: April 22, 2005
    Publication date: November 8, 2007
    Inventors: Katarina Edwards, Stefan Sjoberg, Jorgen Carlsson, Lars Gedda